```html

Quintessential Eczema (Atopic Dermatitis)

Overview

Atopic dermatitis (AD), often called “quintessential eczema,” is a chronic, relapsing inflammatory skin disease characterized by intense itching and dry, scaly lesions. It is one of the most common skin conditions worldwide, affecting people of all ages but typically beginning in childhood.

• Prevalence: Approximately 10‑20% of children and 2‑10% of adults worldwide have AD (World Health Organization, 2023).
• Gender: Slightly more common in females after puberty.
• Age of onset: 60‑70% of cases start before age 2; 30‑40% begin after age 5.
• Geography: Higher rates in industrialized nations and urban areas, likely due to environmental and lifestyle factors.

Symptoms

Symptoms can vary by age, body location, and disease severity. The hallmark is **pruritus (itching)**, which often leads to a cycle of scratching and worsening inflammation.

Cutaneous signs

• Dry, scaly skin (xerosis): Often the first sign, especially on the hands, forearms, and shins.
• Eczematous plaques: Red, inflamed, and thickened (lichenified) patches. In infants, they appear as “flexural” (inside elbows/knees) or on the face and scalp.
• Excoriations: Linear scratches from persistent itching.
• Crusting or oozing (weeping): Seen during acute flares, especially in children.
• Hyperpigmentation or hypopigmentation: Post‑inflammatory changes after lesions heal.
• Koebner phenomenon: New lesions develop at sites of skin trauma (e.g., scrapes, rubbing).

Systemic and associated features

• Sleep disturbance due to night‑time itching.
• Secondary bacterial infection (often Staphylococcus aureus).
• Increased serum IgE levels and eosinophilia.
• Associated atopic conditions: asthma, allergic rhinitis, food allergies.

Causes and Risk Factors

Atopic dermatitis is multifactorial; no single cause accounts for all cases.

Genetic predisposition

• Mutations in the FLG gene (filaggrin) impair skin barrier function, present in up to 30% of moderate‑to‑severe AD patients.
• Family history of eczema, asthma, or hay fever increases risk three‑fold.

Immune system dysregulation

• Over‑activation of Th2‑type cytokines (IL‑4, IL‑13) drives inflammation and IgE production.

Environmental triggers

• Dry climate, low humidity, and extreme temperatures.
• Contact with irritants (soaps, detergents, wool, certain metals).
• Allergens: dust mites, pet dander, pollens, certain foods.
• Stress and emotional factors can precipitate flares.

Other risk factors

• Male gender in early childhood, female after puberty.
• Premature birth or low birth weight.
• Living in urban settings with higher pollution levels.

Diagnosis

Diagnosis is primarily clinical, based on history and physical examination. No single laboratory test confirms AD, but investigations help assess severity, rule out mimickers, or detect complications.

Clinical criteria

• Hanifin & Rajka criteria (1980): Requires ≥3 major + ≥3 minor features (e.g., pruritus, typical distribution, chronic/relapsing course).
• UK Working Party criteria (1994): Simpler algorithm used in primary care.

Complementary tests (when indicated)

• **Skin prick or specific IgE testing** – to identify allergen sensitivities.
• **Bacterial culture** – if infection suspected (e.g., crusted lesions, pustules).
• **Blood eosinophil count or total IgE** – supportive, not diagnostic.
• **Patch testing** – if contact dermatitis is in the differential.

Treatment Options

Therapy aims to control inflammation, repair the skin barrier, and minimize triggers. Treatment is tiered according to severity (mild, moderate, severe).

1. Skin‑care basics (all stages)

• Emollient therapy: Apply fragrance‑free moisturizers ≥2 times daily; “wet‑wrap” technique for acute flares.
• Gentle cleansing: Use mild, pH‑balanced cleansers; avoid hot water.
• Trigger avoidance: Identify and limit exposure to known irritants or allergens.

2. Topical medications

• Topical corticosteroids (TCS): First‑line for active lesions. Choose potency based on site and age (e.g., hydrocortisone 1% for face, clobetasol propionate 0.05% for thick plaques).
• Topical calcineurin inhibitors (TCIs): Tacrolimus 0.03‑0.1% ointment or pimecrolimus 1% cream—useful for delicate areas (face, intertriginous zones) and steroid‑sparing.
• Phosphodiesterase‑4 inhibitor cream (crisaborole): Non‑steroidal option for mild–moderate disease.

3. Systemic therapies (moderate‑severe or refractory disease)

• Phototherapy: Narrow‑band UVB 3‑5 times/week; effective for many adults.
• Oral immunosuppressants: Cyclosporine, methotrexate, azathioprine—reserved for short‑term use due to toxicity.
• Biologic agents: Dupilumab (anti‑IL‑4Rα) is FDA‑approved for adults and adolescents; emerging agents include tralokinumab (IL‑13) and lebrikizumab.
• JAK inhibitors: Oral upadacitinib and baricitinib, and topical ruxolitinib, have shown rapid itch relief.

4. Management of secondary infection

• Topical antibiotics (mupirocin, fusidic acid) for limited bacterial colonization.
• Oral antibiotics (e.g., cephalexin, clindamycin) for extensive impetiginized lesions.

5. Adjunctive therapies

• Antihistamines for nighttime itch (sedating first‑generation agents).
• Wet‑wrap dressings (moist gauze + dry layer) to enhance moisturizer absorption during acute flares.
• Psychological support or cognitive‑behavioral therapy to address itch‑scratch cycle and stress.

Living with Quintessential Eczema (Atopic Dermatitis)

Effective self‑management reduces flare frequency and improves quality of life.

Daily skin‑care routine

1. Morning: Cleanse with lukewarm water + mild cleanser → pat dry → apply thick moisturiser (cream or ointment).
2. Evening: Repeat cleanse if needed, then use any prescribed topical medication, finish with moisturiser.
3. After bathing: Apply moisturizer within 3 minutes while skin is still damp (the “seal‑in” method).

Clothing and environment

• Wear soft, breathable fabrics (cotton, bamboo). Avoid wool, synthetic fibers that irritate.
• Keep indoor humidity between 40‑60%; use a humidifier in dry climates.
• Maintain a cool ambient temperature; excessive sweating worsens itch.

Trigger log

Maintain a diary noting foods, activities, stress levels, and skin status. Patterns often reveal avoidable triggers.

Stress management

• Mindfulness, yoga, or short daily meditation.
• Regular exercise (non‑sweaty activities like walking) improves skin barrier function.

When to contact your clinician

• New or worsening lesions despite adherence to treatment.
• Signs of infection (increased redness, warmth, pus, fever).
• Difficulty sleeping because of itch.
• Any concern about side‑effects of prescribed medication.

Prevention

While AD cannot be “cured,” several strategies lower flare risk.

1. Early moisturisation: Initiate regular emollient use in infants at high risk (e.g., with a parent who has eczema).
2. Breastfeeding: Some studies suggest a modest protective effect against early‑onset AD.
3. Allergen avoidance: For known food allergies, maintain an elimination diet under dietitian supervision.
4. Environmental control: Use dust‑mite‑proof bedding, keep pets out of the bedroom, and reduce indoor pollutants.
5. Skin‑barrier protection: Apply barrier creams (e.g., zinc oxide) before exposure to irritants such as diaper rash or prolonged water contact.

Complications

If inadequately controlled, AD can lead to a range of short‑ and long‑term problems.

• Infection: Bacterial (S. aureus, Streptococcus), viral (eczema herpeticum), or fungal (Candida) superinfection.
• Skin‑type changes: Lichenification, hyperpigmentation, or atrophic scarring.
• Psychosocial impact: Depression, anxiety, and impaired social functioning, especially in adolescents.
• Sleep deprivation: Chronic itching disrupts sleep, affecting cognition and mood.
• Increased risk of other atopic diseases: Asthma and allergic rhinitis may develop later in life.
• Rare systemic effects: Persistent inflammation may be associated with elevated cardiovascular risk in severe adult disease (observational data, NIH 2022).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, JAMA Dermatology, British Journal of Dermatology, American Academy of Dermatology guidelines (2023).

```